G Tournaire1, F Despas2, F Huguet3, J L Montastruc1, E Bondon-Guitton1. 1. Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de Pharmacovigilance, Pharmacoépidémiologie et Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Faculté de Médecine de l'Université de Toulouse, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. 2. Service de Pharmacologie Médicale et Clinique, Faculté de Médecine de l'Université de Toulouse, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. 3. Service d'Hématologie, Institut Universitaire du Cancer, Toulouse, France.
Abstract
WHAT IS KNOWN AND OBJECTIVE: Peripheral vascular adverse events have been reported with ponatinib treatment in chronic myeloid leukaemia (CML) after failure of dasatinib or nilotinib. We here report peripheral arterial occlusive disease (PAOD) in a patient who had previously received only imatinib as tyrosine kinase inhibitor. CASE DESCRIPTION: The patient was a 70-year-old man with no history of cardiovascular disease. He developed arterial hypertension 5 months after the initiation of ponatinib and PAOD 41 months later. WHAT IS NEW AND CONCLUSION: Peripheral arterial occlusive disease can occur several years after the initiation of ponatinib in patients who had previously received only imatinib. Long-term surveillance is required for preventing the complications of ponatinib-associated PAOD.
WHAT IS KNOWN AND OBJECTIVE: Peripheral vascular adverse events have been reported with ponatinib treatment in chronic myeloid leukaemia (CML) after failure of dasatinib or nilotinib. We here report peripheral arterial occlusive disease (PAOD) in a patient who had previously received only imatinib as tyrosine kinase inhibitor. CASE DESCRIPTION: The patient was a 70-year-old man with no history of cardiovascular disease. He developed arterial hypertension 5 months after the initiation of ponatinib and PAOD 41 months later. WHAT IS NEW AND CONCLUSION: Peripheral arterial occlusive disease can occur several years after the initiation of ponatinib in patients who had previously received only imatinib. Long-term surveillance is required for preventing the complications of ponatinib-associated PAOD.
Authors: Jesus Paez-Mayorga; Andrew L Chen; Sivareddy Kotla; Yunting Tao; Rei J Abe; Emma D He; Brian P Danysh; Marie-Claude C Hofmann; Nhat-Tu Le Journal: Front Cardiovasc Med Date: 2018-09-06